一分钟看懂
这是一项关于Thyroid Cancer的I 期 / II 期研究，登记的药物或干预包括68Ga-DOTA-TATE PET Scan；Amino acid infusions；177Lu-DOTA-EB-TATE，当前状态为尚未开始招募。登记地点显示中国Bethesda有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
68Ga-DOTA-TATE PET Scan；Amino acid infusions；177Lu-DOTA-EB-TATE · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- National Institutes of Health Clinical Center · Bethesda
公开的入选条件
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- * Aged 18 years or older.
- * Metastatic RAI-non-responsive and/or RAI-non-avid oncocytic (Hurthle cell) thyroid cancer.
- * Progressive disease by RECIST 1.1 criteria, with or without symptoms within the last 12 months. This applies to patients with non-measurable disease by RECIST 1.1 criteria, who will be eligible if they have evidence of progression as defined by the developme
- * High expression of SSTR2 in at least one metastatic lesion as documented by 68Ga-DOTATATE PET/CT with SUVmax \> SUVmax of the liver consistent with Krenning score of \>2 or SUVmax \>= 13 based on scan performed within 12 weeks of anticipated enrollment.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06991738；登记信息更新于 2026-09-17。